alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
|EXHIBIT 31.2
|------------

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF2002



|I, Xiaoling Chen, certify that:
|-------------------------------

1. I have reviewed this report on Form 10-K (Report) of Asia Electrical Power International Inc.;

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this Report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this Report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

c) Disclosed in this Report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5. I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

---

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.



|Date: April 10, 2008
|--------------------

/s/ Xiaoling Chen

Xiaoling Chen, Chief Accounting Officer, Secretary and Director

---
EXHIBIT 32.1





CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002





In
connection with the annual report of Pharma-Bio Serv, Inc. (the
“Company”) on Form 10-K/A for the fiscal year ended
October 31, 2019 as filed with the Securities and Exchange
Commission on the date hereof (the “report”), the
undersigned, Victor Sanchez, Chief Executive Officer of the
Company, and Pedro J. Lasanta, Chief Financial Officer of the
Company, each certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002,
that to our knowledge:





1.
 The
report fully complies with the requirements of Section 13(a) or
Section 15(d) of the Securities Exchange Act of 1934, as amended;
and


2.
 The information contained in the report fairly
presents, in all material respects, the financial
condition and results of
operation of the Company.








Dated:
February 28, 2020





/s/ Victor Sanchez

/s/ Pedro J. LasantaVictor Sanchez
Chief Executive Officer(principal executive officer)

Pedro J. Lasanta
Chief Financial Officer
(principal financial and accounting officer)








This certification accompanies the Form 10-K/A to which it relates,
is not deemed filed with the Securities and Exchange Commission and
is not to be incorporated by reference to any filing of Pharma-Bio
Serv, Inc. under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended (whether made before or
after the date of the Form 10-K/A), irrespective of any general
incorporation language contained in such filing.
##### 



Exhibit 99.2 ANNUAL STATEMENT OF COMPLIANCEPrincipal Life Income Fundings Trust 2004-51 (the Trust) I, Nancy H. Forte, a duly elected and acting officer of Citibank, N.A. (Indenture Trustee),
do hereby certify on behalf of the Indenture Trustee, that: 1. I have reviewed and examined the performance by the Indenture Trustee of the application of
trust money collected by the Indenture Trustee pursuant to Section 5.02 and, if applicable, Section
6.06 of the Indenture pursuant to which the Trusts notes were issued during the fiscal year ending
December 31, 2004 (the Relevant Year); and 2. Based upon my review and examination described in 1 above, and except as provided in the
Report of Independent Registered Public Accounting Firm on Compliance, dated March 15, 2005,
prepared by the Ernst & Young LLP substantially in accordance with Section 4.05 of the Expense and
Indemnity Agreement, to the best of my knowledge, the application of trust money collected by the
Indenture Trustee pursuant to Section 5.02 and, if applicable, Section 6.06 of the Indenture was
performed in accordance with the terms of the Indenture throughout the Relevant Year. CITIBANK, N.A., as Indenture Trustee By:

/s/
Nancy H. ForteName:
    Nancy H. ForteTitle:
    Assistant Vice President Date: March 29, 2005
Extension of Employment Agreement - Evans


 Exhibit 10.7 
 Mutual Consent to Extend Employment Term 
 In connection with that certain Amended
and Restated Employment Agreement between Kensey Nash Corporation and Douglas G. Evans, P.E., entered into as of January 1, 2009, and as amended through the date hereof (the “Agreement”), the parties thereto (1) acknowledge that
the term of the Agreement will automatically expire on June 27, 2012, if not extended, and (2) mutually agree to extend the term of the Agreement to June 27, 2014, pursuant to Section 3(a) of the Agreement. Except to the extent
necessary to give effect to the foregoing extension, the Agreement will otherwise remain unchanged and in full force and effect. 
 IN WITNESS WHEREOF, the undersigned, as parties to the Agreement, have caused this Mutual Consent to be executed as of the 21st day of October, 2011. This Mutual Consent may be executed in counterparts, each of which shall be deemed an original
and when taken together shall constitute one agreement. 
  

							
	Executive	 		 	Kensey Nash Corporation
				
	 /s/ Douglas G. Evans, P.E.
	 		 	By:	 	 /s/ Joseph W. Kaufmann

	Douglas G. Evans, P.E.	 		 	Name:	 	Joseph W. Kaufmann
		 		 	Title:	 	President and Chief Executive Officer
II 

112TH CONGRESS 

2D SESSION S. 2628 

To extend the temporary suspension of duty on formulations of 

Thiamethoxam, Difenoconazole, Fludioxinil, and Mefenoxam. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. NELSON of Nebraska introduced the following bill; which was read twice 

and referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on formulations 

of Thiamethoxam, Difenoconazole, Fludioxinil, and 

Mefenoxam. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. FORMULATIONS OF THIAMETHOXAM, 

4 DIFENOCONAZOLE, FLUDIOXINIL, AND 

5 MEFENOXAM. 

6 (a) IN GENERAL.—Heading 9902.13.31 of the Har7 monized Tariff Schedule of the United States (relating to 

8 formulations of Thiamethoxam, Difenoconazole, 

9 Fludioxinil, and Mefenoxam) is amended by striking the 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 2628 IS

1 date in the effective period column and inserting ‘‘12/31/ 

2 2015’’. 

3 (b) EFFECTIVE DATE.—The amendment made by 

4 subsection (a) applies with respect to goods entered, or 

5 withdrawn from warehouse for consumption, on or after 

6 the 15th day after the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
<PAGE>

                  GENWORTH LIFE AND ANNUITY INSURANCE COMPANY

                           DEATH BENEFIT ENDORSEMENT

This endorsement amends [Proceeds When Death Occurs Before Income Payments
Begin], under the DEATH PROVISIONS section of the Contract by adding the
following language:

Notwithstanding the [Designated Beneficiary] paragraph, the Owner may, by
providing written notice in a manner acceptable to the Company, choose the
method of payment of death proceeds under the Contract by selecting any Payment
Choice, including any Optional Payment Plan, that the Designated
Beneficiary(ies) may have chosen. The Designated Beneficiaries cannot change
any Payment Choice that the Owner has selected. If the Owner makes a Payment
Choice for the surviving spouse, the spouse may not continue the Contract in
accordance with the [Distribution Rules When Death Occurs Before Income
Payments Begin] paragraph. The Owner may also specify at the time of electing
an Income Payment Option that any payments remaining to be made at the Owner's
death cannot be commuted or assigned. While living, the Owner may revoke any
such limitations on the rights of the Designated Beneficiary by providing
written notice of such revocation in a manner acceptable to the Company. If the
Payment Choice selected by the Owner does not apply to a Designated
Beneficiary, the limitations imposed by this Endorsement shall be removed as to
such Designated Beneficiary. For example, a Payment Choice based on an
individual's life does not apply to the Owner's estate and the estate would be
free to make its own Payment Choice as Designated Beneficiary after the Owner's
death.

For Genworth Life and Annuity Insurance Company,

                              /s/ Pamela S. Schutz
                              --------------------
                                Pamela S. Schutz
                                   President

 P5360 07/07                          1
UNPUBLISHED

UNITED STATES COURT OF APPEALS 

FOR THE FOURTH CIRCUIT 

No. 09-2049

CHARMAINE DENISE JACKSON, 

 Plaintiff - Appellant, 

 v. 

AMERICAN HEALTHWAYS GOVERNMENT SERVICES, INC.; AMERICAN 

HEALTHWAY SERVICES, INC., 

 Defendants - Appellees. 

Appeal from the United States District Court for the District of 

Maryland, at Greenbelt. Peter J. Messitte, Senior District 

Judge. (8:07-cv-03244-PJM) 

Submitted: January 19, 2010 Decided: January 26, 2010 

Before NIEMEYER, KING, and DAVIS, Circuit Judges. 

Affirmed by unpublished per curiam opinion. 

Charmaine Denise Jackson, Appellant Pro Se. Peter Woodward 

Sheehan, Melissa Menkel Shorey, WHITEFORD, TAYLOR & PRESTON, 

LLP, Baltimore, Maryland, for Appellees.

Unpublished opinions are not binding precedent in this circuit. 
2 

PER CURIAM: 

Charmaine Denise Jackson appeals the district court’s 

orders granting Appellees’ motion for summary judgment and 

denying Appellant’s motions for counsel and to reopen discovery. 

We have reviewed the record and find no reversible error. 

Accordingly, we affirm for the reasons stated by the district 

court. Jackson v. Am. Healthways Gov’t Servs., Inc., No. 8:07-

cv-03244-PJM (D. Md. Aug. 12, 2009). We dispense with oral 

argument because the facts and legal contentions are adequately 

presented in the materials before the court and argument would 

not aid the decisional process. 

AFFIRMED
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 20-0138

STATE OF MONTANA,

Plaintiff and Appellee,

v.

WILLIAM CURTIS SMALL,

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time, 

and good cause appearing,

IT IS HEREBY ORDERED that Appellant is granted an extension 

of time to and including January 31, 2022, within which to prepare, file, 

and serve Appellant’s opening brief on appeal.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

December 15 2021

12/15/2021

Case Number: DA 20-0138
Exhibit 32.2

CERTIFICATION  PURSUANT TO 18 U.S.C. SECTION 1350,  AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Gerald M. Sherer, as Chief Financial Officer of Refco Group Ltd., LLC and Refco Finance Inc. (together, the
"Company"), certify, pursuant to 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)   the
accompanying Annual Report on Form 10-K for the period ending February 28, 2005 as filed with the U.S. Securities and Exchange Commission
(the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)   the
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:
June 30, 2005

| |  |  | /s/GERALD M. SHERER                     
| |  |  | ----------------------------------------
| |  |  | Gerald M. Sherer
Chief Financial Officer

---



QuickLinks
Shaquan PARKER, Appellant/Petitioner(s), v. USA SERVICES OF FLORIDA, INC. and Lance M. McLendon, Appellee/Respondent(s).

CASE NO.: 2D17-1042

District Court of Appeal of Florida, Second District.

August 10, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the annual report on Form 10-K of Pharmasset, Inc. (the Company) for the
period ended September 30, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Kurt Leutzinger, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C.
Section 1350 as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                       
|-----------------------
|Date: December 11, 2008
|                       
|/s/    KURT LEUTZINGER 
|Kurt Leutzinger        
|Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to
Pharmasset, Inc. and will be retained by Pharmasset, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<ARTICLE> 9

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                      14,621,000
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                             2,174,000
<INVESTMENTS-HELD-FOR-SALE>                 39,413,000
<INVESTMENTS-CARRYING>                      14,449,000
<INVESTMENTS-MARKET>                        14,351,000
<LOANS>                                    329,197,000
<ALLOWANCE>                                  2,967,000
<TOTAL-ASSETS>                             424,678,000
<DEPOSITS>                                 293,064,000
<SHORT-TERM>                                83,337,000
<LIABILITIES-OTHER>                         12,816,000
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     2,685,000
<OTHER-SE>                                  32,776,000
<TOTAL-LIABILITIES-AND-EQUITY>             424,678,000
<INTEREST-LOAN>                             20,313,000
<INTEREST-INVEST>                            2,270,000
<INTEREST-OTHER>                               486,000
<INTEREST-TOTAL>                            23,069,000
<INTEREST-DEPOSIT>                           9,058,000
<INTEREST-EXPENSE>                          11,613,000
<INTEREST-INCOME-NET>                       11,456,000
<LOAN-LOSSES>                                  677,000
<SECURITIES-GAINS>                              16,000
<EXPENSE-OTHER>                             20,829,000
<INCOME-PRETAX>                              1,597,000
<INCOME-PRE-EXTRAORDINARY>                   1,597,000
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,247,000
<EPS-BASIC>                                        .48
<EPS-DILUTED>                                      .48
<YIELD-ACTUAL>                                    4.19
<LOANS-NON>                                  1,202,000
<LOANS-PAST>                                   552,000
<LOANS-TROUBLED>                               782,000
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                             2,709,000
<CHARGE-OFFS>                                  502,000
<RECOVERIES>                                    83,000
<ALLOWANCE-CLOSE>                            2,967,000
<ALLOWANCE-DOMESTIC>                         2,967,000
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 97-7564
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus MICHAEL HUNTER, a/k/a Big Mike, Defendant - Appellant.Appeal from the United States District Court for the Eastern District of Virginia, at Norfolk. John A. MacKenzie, Senior District Judge. (CR-93-156, CA-97-431-2) Submitted: February 10, 1998 Decided: March 17, 1998 Before MURNAGHAN and WILKINS, Circuit Judges, and PHILLIPS, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Michael Hunter, Appellant Pro Se. Fernando Groene, OFFICE OF THE UNITED STATES ATTORNEY, Norfolk, Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM:Appellant appeals the district court's order denying his motion filed under 28 U.S.C.A. § 2255 (West 1994 & Supp. 1997). We have reviewed the record and the district court's opinion and find no reversible error. Appellant asserts that the district court erroneously sentenced him pursuant to 21 U.S.C. § 841(b)(1)(A)(iii)(1994). We find that Appellant has waived review of this nonconstitutional claim because he did not raise it at sentencing or on direct appeal. See Stone v. Powell , 428 U.S. 465, 477 n.10 (1976); United States v. Emanuel , 869 F.2d 795, 796 (4th Cir. 1989). In addition, to the extent that Appellant contends that counsel was ineffective at sentencing and on appeal for failing to assert that Appellant was improperly sentenced under § 841(b), we find that claim to be without merit. See Strickland v. Washington, 466 U.S. 668 (1984).Accordingly, we deny a certificate of appealability and dismiss this appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
II 

112TH CONGRESS 

2D SESSION S. 2731 

To extend the temporary suspension of duty on certain pressure distillation 

columns. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. CASEY introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on certain 

pressure distillation columns. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN PRESSURE DISTILLATION COLUMNS. 

4 (a) IN GENERAL.—Heading 9902.40.36 of the Har5 monized Tariff Schedule of the United States (relating to 

6 certain pressure distillation columns) is amended by strik7 ing the date in the effective period column and inserting 

8 ‘‘12/31/2015’’. 

9 (b) EFFECTIVE DATE.—The amendment made by 

10 subsection (a) applies to goods entered, or withdrawn from 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•S 2731 IS

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 2863 

To suspend temporarily the duty on 4,4′-butylidenebis [3-methyl 6 tert 

butylphenol]. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. PRYOR introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on 4,4′-butylidenebis [3- 

methyl 6 tert butylphenol]. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 4,4′-BUTYLIDENEBIS [3-METHYL 6 TERT BUTYL4 PHENOL]. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.01.00 4,4′-Butylidenebis[3-methyl 6 

tert butylphenol] (CAS No. 

85–60–9) (provided for in 

subheading 2907.29.90) ........ Free No change No change On or before 

12/31/2015 ’’. 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 2863 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
A.L. v. TUSCALOOSA COUNTY DEPARTMENT OF HUMAN RESOURCES

2150807

Court of Civil Appeals of Alabama.

January 13, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Exhibit 10.75

 

Change Order Form # 6

 

Change order under Agreement dated:  Third Amendment to Development and Clinical Supplies Agreement dated 29 September 2010

 

Between:  Radius Health, Inc and 3M

 

Project Name:  For the development of Radius’s BA-058 compound delivered via 3M’s Microstructured Transdermal Delivery System




 

Change requested by:  Radius

 

Name:  Gary Hattersley

Company:  Radius

Date:  1 June 2011

 

Description of change:

 

3M has been requested to add 5oC

8-month stability pull for CM-10-00503

3-month stability pull for TM-10-00569

3-month stability pull for TM-10-00570

4-month stability pull for TM-10-00584

@ [*] each pull.*

 

 

 

 

 

 

In all other respects, the terms and conditions of the Agreement remain in full force and effect.




Requested task, dates and costs are approved by:

 

	
Company:   Radius Health, Inc
    	
 
    	
Company:   3M
    
	
Name:   Nick Harvey
    	
 
    	
Name:   Mary Mathisen
    
	
Signature:   /s/ Nick Harvey
    	
 
    	
Signature:   /s/ Mary Mathisen
    
	
Position:   CFO
    	
 
    	
Position:   Commercialization Mgr
    
	
Date   (dd/mm/yy): 6/16/11
    	
 
    	
Date   (dd/mm/yy): 6/20/2011
    


 




* Confidential Treatment Requested by the Registrant.  Redact Portion Filed Separately with the Commission.

 

1